Barclays lowered the firm’s price target on Biomea Fusion (BMEA) to $3 from $11 and keeps an Equal Weight rating on the shares following the Q4 report. The company’s catalysts are on track with a focus around a path forward for icovamenib, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA:
- Biomea Fusion’s Strategic Shift: A Year of Transformation
- Biomea Fusion reports Q4 EPS (81c), consensus (93c)
- Buy Rating for Biomea Fusion’s Icovamenib: A Promising Breakthrough in Diabetes Treatment
- Biomea Fusion Appoints Interim CEO Amid Leadership Changes
- Biomea Fusion names Mick Hitchcock to succeed Thomas Butler as interim CEO